SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that partners of the company will present new interim data from two phase I clinical trials of plasmid-based immunotherapies using Inovio’s electroporation delivery technology at the Third International Conference on DNA Vaccines in Malaga, Spain, being held May 23-25, 2007 at the Torrequebrada Hotel. Dr. Christian Ottensmeier of the University of Southampton will present data relating to a prostate cancer vaccine. Dr. Richard Heller of the University of South Florida and Moffitt Cancer Center will present data on a melanoma immunotherapy study. These clinical studies are assessing safety, tolerability and immune responses of these products in conjunction with Inovio’s electroporation-based DNA delivery technologies, which are designed to enhance the potency of immunotherapies including DNA vaccines.
